ASTRAZENECA CONTACT ANNUAL REPORT AND INFORMATION FORM 20-F INFORMATION 2007 REGISTERED OFFICE INVESTOR RELATIONS REGISTRAR AND US DEPOSITARY AND CORPORATE CONTACTS TRANSFER OFFICE JPMorgan Chase Bank HEADQUARTERS ADDRESS UK: as above or e-mail Equiniti Limited JPMorgan Service Center AstraZeneca PLC IR@astrazeneca.com Aspect House PO Box 3408 15 Stanhope Gate Sweden: Spencer Road South Hackensack London W1K 1LN AstraZeneca AB Lancing NJ 07606-3408 UK SE-151 85 Södertälje West Sussex US Tel: +44 (0)20 7304 5000 Sweden BN99 6DA Tel (toll free in the US): Fax: +44 (0)20 7304 5151 Tel: +46 (0)8 553 260 00 UK 888 697 8018 Fax: +46 (0)8 553 290 00 Tel (freephone in the UK): Tel (outside the US): or e-mail 0800 389 1580 +1 (201) 680 6630 IR@astrazeneca.com Tel (outside the UK): US: +44 (0)121 415 7033 Investor Relations AstraZeneca SWEDISH SECURITIES ASTRAZENECA.COM Pharmaceuticals LP REGISTRATION CENTRE 1800 Concord Pike VPC AB PO Box 15437 PO Box 7822 Wilmington SE-103 97 Stockholm DE 19850-5437 Sweden US Tel: +46 (0)8 402 9000 Tel: +1 (302) 886 3000 Fax: +1 (302) 886 2972 2007 AND FORM 20-F INFORMATION ANNUAL REPORT ASTRAZENECA This Annual Report and Form 20-F Information is also available online at astrazeneca.com/ annualreport2007 INTRODUCTION 01 > International accounting transition 92 26 Employee costs and share option plans for employees 153 AstraZeneca and our year in brief 01 > New accounting standards 92 > Sarbanes-Oxley Act section 404 92 27 Commitments and Financial highlights 02 contingent liabilities 158 > Results of operations – summary Chairman’s statement 04 analysis of year to 31 December 2006 93 28 Leases 174 Chief Executive Offi cer’s review 05 > Financial position, including 29 Statutory and other information 175 cash fl ow and liquidity – 2006 95 30 Share capital of parent company 176 DIRECTORS’ REPORT 08 Principal subsidiaries 177 REMUNERATION REPORT 98 Goals, strategy and Independent auditors’ performance measurement 09 report to the members of AstraZeneca PLC (Company) 178 Business environment 13 FINANCIAL STATEMENTS 116 Company balance sheet 179 Business organisation 17 Preparation of the Financial Accounting policies (Company) 180 > Board of Directors at Statements and Directors’ 31 December 2007 18 responsibilities 116 Notes to the Financial > Chief Executive Offi cer, delegation of Directors’ responsibilities for, Statements (Company) 181 authority and Senior Executive Team 20 and report on, internal control 1 Fixed asset investments 181 Our resources, skills and capabilities 21 over fi nancial reporting 116 2 Other debtors 181 > Medicines 21 Auditors’ reports on the Financial 3 Non-trade creditors 181 > Research and development 23 Statements and on internal control 4 Loans 181 > R&D governance and over fi nancial reporting 5 Reserves 182 portfolio management 27 (Sarbanes-Oxley Act section 404) 117 6 Reconciliation of movement in > Development pipeline Independent auditors’ shareholders’ funds 182 at 31 January 2008 28 report to the members of 7 Share capital 182 > Sales and marketing 31 AstraZeneca PLC (Group) 117 8 Commitments and > Intellectual property 33 contingent liabilities 183 Consolidated income statement 118 > Supply and manufacturing 33 9 Statutory and other information 183 Consolidated statement of > People 35 Group fi nancial record 184 recognised income and expense 118 > Main facilities 37 Consolidated balance sheet 119 Corporate governance ADDITIONAL INFORMATION 186 and managing risk 38 Consolidated cash fl ow statement 120 Shareholder information 186 Cardiovascular (CV) medicines 50 Accounting policies (Group) 121 Risk 193 Gastrointestinal (GI) medicines 53 Notes to the Financial Statements (Group) 124 Corporate information 200 Neuroscience medicines 56 1 Operating profi t 124 Cross-reference to Form 20-F 201 Oncology medicines 59 2 Restructuring and synergy costs 124 Glossary 202 Respiratory and Infl ammation 3 Finance income and expense 125 (R&I) medicines 63 Cautionary statement regarding 4 Taxation 125 forward-looking statements Trade marks Statements of competitive position Trade marks of the AstraZeneca group of companies Except as otherwise stated, market information Infection medicines 66 5 Earnings per $0.25 Ordinary Share 127 The purpose of this Annual Report and Form 20-F Information is to provide information to the members appear throughout this document in italics. in this Annual Report and Form 20-F Information Other businesses 68 6 Segment information 128 of the Company. In order, among other things, to AstraZeneca, the AstraZeneca logotype and the regarding the position of our business or products AstraZeneca symbol are all trade marks of the relative to its or their competition is based upon Geographical review 69 7 Product sales information 130 utilise the ‘safe harbour’ provisions of the US Private Securities Litigation Reform Act 1995 and the UK AstraZeneca group of companies. Trade marks published statistical data for the 12 months ended 8 Property, plant and equipment 131 Companies Act 2006, we are providing the following of companies other than AstraZeneca appear with 30 September 2007, obtained from IMS Health, In the global community 73 ® ™ ® cautionary statement: This Annual Report and a or sign and include: Abraxane , a registered a leading supplier of statistical data to the 9 Goodwill 132 ™ Environmental review 75 Form 20-F Information contains certain forward- trade mark of Abraxis BioScience, Inc.; Aspirin , pharmaceutical industry. Except as otherwise ™ 10 Intangible assets 133 looking statements with respect to the operations, a trade mark of Bayer AG; Avastin , a trade mark of stated, these market share and industry data from Financial review 77 ™ 11 Other investments 134 performance and fi nancial condition of the Group. Genentech, Inc.; BiTE , developed by Micromet, Inc. IMS Health have been derived by comparing our ™ > Measuring performance 77 Although we believe our expectations are based and MedImmune, Inc.; Cubicin , a trade mark of sales revenue to competitors’ and total market 12 Inventories 134 Cubist Pharmaceuticals, Inc.; CyDex Captisol™, sales revenues for that period. For the purposes of > Business background and on reasonable assumptions, any forward-looking 13 Trade and other receivables 135 statements, by their very nature, involve risks and a trade mark of CyDex Pharmaceuticals Inc.; this Annual Report and Form 20-F Information, major events affecting 2007 78 ™ ™ uncertainties and may be infl uenced by factors that CytoFab , a trade mark of Protherics, Inc.; Herceptin , references to the world pharmaceutical market or 14 Cash and cash equivalents 135 ™ > Results of operations – summary could cause actual outcomes and results to be a trade mark of Genentech, Inc.; Humira , a trade similar phrases are to 52 countries contained in IMS ™ analysis of year to 31 December 2007 79 15 Interest bearing loans materially different from those predicted. The forward- mark of Abbott Biotechnology Ltd.; Lean Sigma , Health’s MIDAS Quantum database, which amount to and borrowings 135 looking statements refl ect knowledge and information a trade mark of Smallpiece Enterprises Limited; approximately 95% (in value) of the countries audited > Financial position, including ™ ™ available at the date of the preparation of this Annual Prinivil , a trade mark of Merck & Co., Inc.; Seretide , by IMS Health. cash fl ow and liquidity 81 16 Financial risk management ™ Report and Form 20-F Information and the Company a trade mark of GlaxoSmithKline; Taxotere , a trade Statements of growth rates, sales objectives and policies 136 ™ > Acquisition of MedImmune 83 undertakes no obligation to update these forward- mark of Aventis Pharma SA; TriCor , a trade mark of and market data ™ 17 Financial instruments 138 looking statements. We identify the forward-looking Fournier Industrie et Santé; Zocor , a trade mark of Except as otherwise stated, growth rates and sales in > Restructuring and synergy costs 84 ™ 18 Trade and other payables 142 statements by using the words ‘anticipates’, ‘believes’, Merck & Co., Inc.; and Zyprexa , a trade mark of this Annual Report and Form 20-F Information > Capitalisation and shareholder return 84 Eli Lilly and Company. 19 Provisions for liabilities and charges 142 ‘expects’, ‘intends’ and similar expressions in such are given at constant exchange rates (CER) to show > Future prospects 84 statements. Important factors that could cause actual Use of terms underlying performance by excluding the effects of 20 Statement of changes in equity 143 results to differ materially from those contained in In this Annual Report and Form 20-F Information, exchange rate movements. Market data are given > Financial risk management policies 85 21 Reserves 144 forward-looking statements, certain of which are unless the context otherwise requires, ‘AstraZeneca’, in actual US dollars. > Critical accounting policies beyond our control, include, among other things, ‘the Group’, ‘we’, ‘us’ and ‘our’ refer to AstraZeneca 22 Minority interests 145 AstraZeneca websites and estimates 86 those factors identifi ed in the section ‘Risk’ on PLC and its consolidated entities. Information on or accessible through our 23 Dividends to shareholders 145 pages 193 to 199 of this document. Nothing in Statements of dates websites, including astrazeneca.com, > Off-balance sheet transactions, this Annual Report and Form 20-F Information contingent liabilities and commitments 90 24 Acquisitions of business operations 145 Except as otherwise stated, references to days and/or astrazenecaclinicaltrials.com,